The ferrocenyl analogue of clotrimazole, in which the metallocene fragment replaces one of the phenyl rings in the triphenylmethane system, and a related isomer were prepared through the direct substitution of a methoxygroup in the α-position to ferrocene with imidazole in the key step. The obtained ferrocenyl derivatives were spectroscopically characterized and in a preliminary assay for bioactivity their cell growth inhibitory activity on two different human cancer cell lines was evaluated. In comparison with the parent drug the ferrocene analogues displayed about two-fold increase of cytotoxicity on HT29 colorectal cancer cells, whereas comparable activity was displayed against MCF-7 breast cancer cell line.